Read Summary


Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.


  • Please Note

    The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Acute Myeloid Leukemia are not printed in this issue of JNCCN but can be accessed online at

    © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

  • Disclosures for the NCCN Acute Myeloid Leukemia Panel

    At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

    Individual disclosures for the NCCN Acute Myeloid Leukemia Panel members can be found on page 957. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at

    These guidelines are also available on the Internet. For the latest update, visit

  • NCCN Acute Myeloid Leukemia Panel Members

    *Margaret R. O’Donnell, MD/Chair‡ξ

    City of Hope Comprehensive Cancer Center

    *Martin S. Tallman, MD/Vice Chair‡

    Memorial Sloan Kettering Cancer Center

    Camille N. Abboud, MD‡Þξ

    Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

    Jessica K. Altman, MD‡

    Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Frederick R. Appelbaum, MD†Þξ

    Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

    Daniel A. Arber, MD≠

    Stanford Cancer Institute

    Vijaya Bhatt, MD‡

    Fred & Pamela Buffett Cancer Center

    Dale Bixby, MD, PhD‡†Þ

    University of Michigan Comprehensive Cancer Center

    William Blum, MD‡Þ†

    The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

    Steven E. Coutre, MD‡

    Stanford Cancer Institute

    Marcos De Lima, MD‡

    Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

    Amir T. Fathi, MD‡†

    Massachusetts General Hospital Cancer Center

    Melanie Fiorella, MDÞ

    UC San Diego Moores Cancer Center

    James M. Foran, MD†

    Mayo Clinic Cancer Center

    Steven D. Gore, MD‡†

    Yale Cancer Center/Smilow Cancer Hospital

    Aric C. Hall, MD‡†

    University of Wisconsin Carbone Cancer Center

    Patricia Kropf, MD‡

    Fox Chase Cancer Center

    Jeffrey Lancet, MD‡†

    Moffitt Cancer Center

    Lori J. Maness, MD‡

    Fred & Pamela Buffett Cancer Center

    Guido Marcucci, MD†Þ

    City of Hope Comprehensive Cancer Center

    Michael G. Martin, MD†

    St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center

    Joseph O. Moore, MD†

    Duke Cancer Institute

    Rebecca Olin, MD‡

    UCSF Helen Diller Family Comprehensive Cancer Center

    Deniz Peker, MD≠

    University of Alabama at Birmingham Comprehensive Cancer Center

    Daniel A. Pollyea, MD, MS‡Þ†

    University of Colorado Cancer Center

    Keith Pratz, MD†

    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Farhad Ravandi, MD‡

    The University of Texas MD Anderson Cancer Center

    Paul J. Shami, MD‡

    Huntsman Cancer Institute at the University of Utah

    Richard M. Stone, MD‡†

    Dana-Farber/Brigham and Women’s Cancer Center

    Stephen A. Strickland, MD, MSCI‡

    Vanderbilt-Ingram Cancer Center

    Eunice S. Wang, MD‡

    Roswell Park Cancer Institute

    Matthew Wieduwilt, MD, PhD‡ξ

    UC San Diego Moores Cancer Center

    NCCN Staff: Kristina Gregory, RN, MSN, OCN; and Ndiya Ogba, PhD


    *Discussion Section Writing Committee

    Specialties: ‡Hematology/Hematology Oncology; ξBone Marrow Transplantation; ÞInternal Medicine; †Medical Oncology; ≠Pathology

Print Friendly, PDF & Email